Abstract: Methods and compositions are provided for determining whether a subject suffering from a neoplastic condition is responsive to an antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, the subject is genotyped to determine whether the subject has a least one favorable Fc?R polymorphism, e.g., the 131 H/H genotype or the 158 V/V genotype. In addition, reagents, devices and kits thereof, that find use in practicing the subject methods are provided.

Abstract: A wave-wind mutually supplementing power supply system for continuous power generation is disclosed. The system of the present invention has a wave kinetic energy module (10), which comprises a wave energy harnessing unit (100), a transmission shaft (110), a generator unit (120), a torque adjusting unit (130) and an automatic control unit (140). The wave kinetic energy module (10) is disposed on/in a sea and may generate electricity through the motion of sea water. The electricity so generated is combined with a wind power generation device to provide continuous power generation. The automatic control unit (140) has a microprocessor (141) and a sea water motion sensor unit (142) so as to adjust the torque of the transmission shaft and control the activation of the generator unit according to the motion of the sea water.

Abstract: Methods and compositions are provided for determining whether a subject suffering from a neoplastic condition is responsive to an antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, the subject is genotyped to determine whether the subject has a least one favorable Fc?R polymorphism, e.g., the131 H/H genotype or the158 VN genotype. In addition, reagents, devices and kits thereof, that find use in practicing the subject methods are provided.

Abstract: Methods and compositions are provided for determining whether a subject suffering from a neoplastic condition is responsive to an antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, the subject is genotyped to determine whether the subject has a least one favorable Fc?R polymorphism, e.g., the 131 H/H genotype or the 158 V/V genotype. In addition, reagents, devices and kits thereof, that find use in practicing the subject methods are provided.

Abstract: Methods and compositions are provided for determining whether a subject suffering from a neoplastic condition is responsive to an antineoplastic therapy, such as antibody therapy, e.g., Rituximab. In practicing the subject methods, the subject is genotyped to determine whether the subject has a least one favorable Fc?R polymorphism, e.g., the 131 H/H genotype or the 158 V/V genotype. In addition, reagents, devices and kits thereof, that find use in practicing the subject methods are provided.